Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Age and Ageing|August 24, 2006
The control system for the Honda humanoid robotToru Takenaka
Clinical Pharmacology in Drug Development|January 22, 2025
Phase 1 Mass Balance Study of Pizuglanstat: An Investigational Hematopoietic Prostaglandin D Synthase InhibitorRyuzo Hanada, Toru Takenaka
Biological & Pharmaceutical Bulletin|November 6, 2007
Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activityYoh Takekuma, Toru Takenaka, Koujiro Yamazaki, et al.
Journal of Pharmaceutical Sciences|February 13, 2016
Application of a Human Intestinal Epithelial Cell Monolayer to the Prediction of Oral Drug Absorption in Humans as a Superior Alternative to the Caco-2 Cell MonolayerToru Takenaka, Naomoto Harada, Jiro Kuze, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 10, 2014
Human small intestinal epithelial cells differentiated from adult intestinal stem cells as a novel system for predicting oral drug absorption in humansToru Takenaka, Naomoto Harada, Jiro Kuze, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 24, 2021
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114Hikari Araki, Toru Takenaka, Koichi Takahashi, et al.
Biological & Pharmaceutical Bulletin|March 3, 2007
Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysisYoh Takekuma, Toru Takenaka, Masami Kiyokawa, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|July 20, 2006
Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilolYoh Takekuma, Toru Takenaka, Masami Kiyokawa, et al.
Journal of Clinical Pharmacology|February 7, 2020
A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and LiverYuji Kumagai, Tomoe Fujita, Mika Maeda, et al.
Clinical Pharmacology in Drug Development|May 3, 2023
Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of FutibatinibIkuo Yamamiya, Allen Hunt, Toru Takenaka, et al.
Pageof 2